home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

46.19 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Earnings Preview: Exelixis ↗

October 28, 2024

Via Benzinga

1 No-Brainer Stock to Buy With $40 ↗

October 23, 2024

The midcap biotech just became an even better buy.

Via The Motley Fool

Analyst Ratings For Exelixis ↗

October 21, 2024

Via Benzinga

Navigating 16 Analyst Ratings For Exelixis ↗

October 21, 2024

Via Benzinga

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

October 18, 2024

In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

October 15, 2024

From Exelixis, Inc.

Via Business Wire

Key Takeaways From Exelixis Analyst Ratings ↗

October 04, 2024

Via Benzinga

A Closer Look at 5 Analyst Recommendations For Exelixis ↗

September 18, 2024

Via Benzinga

NASDAQ:EXEL, an undervalued stock with good fundamentals. ↗

August 15, 2024

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

October 15, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

October 14, 2024

From Exelixis, Inc.

Via Business Wire

Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas ↗

October 13, 2024

It is Fall clean up time. Sell lagging and sagging companies.

Via Talk Markets

Expert Outlook: Exelixis Through The Eyes Of 5 Analysts ↗

August 08, 2024

Via Benzinga

NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗

September 27, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

2 Growth Stocks to Buy With Less Than $100 ↗

September 26, 2024

No need to break the bank to get in on these likely long-term winners.

Via The Motley Fool

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

September 16, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

September 15, 2024

From Exelixis, Inc.

Via Business Wire

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

September 06, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

August 28, 2024

From Exelixis, Inc.

Via Business Wire

3 Stocks to Buy for a Soft Landing, If There Is One

August 15, 2024

Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes

Via MarketBeat

Topics Economy

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results ↗

August 07, 2024

Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance....

Via Benzinga

US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' ↗

August 07, 2024

Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by...

Via Benzinga

Topics Stocks

Exelixis (EXEL) Q2 2024 Earnings Call Transcript ↗

August 07, 2024

EXEL earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

EXEL stock results show that Exelixis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 06, 2024

From Exelixis, Inc.

Via Business Wire

Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday? ↗

August 06, 2024

U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy...

Via Benzinga

Topics Economy Stocks

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

August 06, 2024

From Exelixis, Inc.

Via Business Wire

US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction ↗

August 06, 2024

Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend.

Via Benzinga

Topics Stocks

Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

July 23, 2024

From Exelixis, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com